Viracta Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2019 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Viracta Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q3 2024.
Viracta Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 494 %.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	494			Sep 30, 2024
Q2 2024	215			Jun 30, 2024
Q1 2024	141			Mar 31, 2024
Q4 2020	-16.4	-135	-114%	Dec 31, 2020
Q3 2020	-23.1	-113	-126%	Sep 30, 2020
Q2 2020	-57.6	-253	-129%	Jun 30, 2020
Q1 2020	-221			Mar 31, 2020
Q4 2019	119			Dec 31, 2019
Q3 2019	89.8			Sep 30, 2019
Q2 2019	196			Jun 30, 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.